Chugai Pharmaceutical Co., Ltd. (CHGCY)

Market Cap	70.71B -6.5%
Revenue (ttm)	8.26B +12.3%
Net Income	2.90B +19.2%
EPS	1.76 +19.2%
Shares Out	n/a
PE Ratio	24.38
Forward PE	n/a
Dividend	0.42 (1.94%)
Ex-Dividend Date	Dec 29, 2026

Volume	219,494
Open	21.37
Previous Close	21.40
Day's Range	20.67 - 21.61
52-Week Range	20.00 - 34.84
Beta	0.55
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 27, 2026

About Chugai Pharmaceutical

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Phesgo, Polivy, and Tecentriq; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept, an immunosuppressant; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi, a spinal muscular...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1925
• Employees: 5,104
• Stock Exchange: OTCMKTS
• Ticker Symbol: CHGCY

Financial Performance

In 2025, Chugai Pharmaceutical's revenue was 1.26 trillion, an increase of 7.46% compared to the previous year's 1.17 trillion. Earnings were 434.01 billion, an increase of 12.06%.

Financial numbers in JPY

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Sep 20, 2026

Data Sources Report a data error